Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD.
Hong DS, et al. Among authors: patnaik a.
Clin Cancer Res. 2023 Jun 13;29(12):2210-2219. doi: 10.1158/1078-0432.CCR-22-3313.
Clin Cancer Res. 2023.
PMID: 37000164
Free PMC article.
Clinical Trial.